Search research articles
Contact Us
Filters
Showing results (201-210 of 237) with videos related to
Page
of 24
Sort By:
Genome Research
|
March 12, 2010
Age-dependent DNA methylation of genes that are suppressed in stem cells is a hallmark of cancer
Andrew E Teschendorff, Usha Menon, Aleksandra Gentry-Maharaj, et al.
Bulletin Du Cancer
|
March 26, 2023
Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria, Swiss AGO, BGOG, CEEGOG, GEICO, and SFOG regarding the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in epithelial ovarian cancer
Philipp Harter, Gerhard Bogner, Luis Chiva, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 1, 2021
Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer
Ignace Vergote, Isabelle Ray-Coquard, Daniel M Anderson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 9, 2016
Double-Blind, Placebo-Controlled, Randomized Phase III Trial Evaluating Pertuzumab Combined With Chemotherapy for Low Tumor Human Epidermal Growth Factor Receptor 3 mRNA-Expressing Platinum-Resistant Ovarian Cancer (PENELOPE)
Christian Kurzeder, Isabel Bover, Frederik Marmé, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 28, 2023
PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1/ENGOT-ov25 trial
Liselore Loverix, Ignace Vergote, Pieter Busschaert, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 12, 2024
Clinical evaluation of a low-coverage whole-genome test for detecting homologous recombination deficiency in ovarian cancer
Romain Boidot, Michael G B Blum, Marie-Pierre Wissler, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 4, 2016
ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer
Christian Marth, Ignace Vergote, Giovanni Scambia, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
June 13, 2015
European Network of Gynaecological Oncological Trial Groups' Requirements for Trials Between Academic Groups and Industry Partners--First Update 2015
Andreas du Bois, Alexander Reuss, Eric Pujade-Lauraine, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
October 22, 2024
How long is long enough? An international survey exploring practice variations on the recommended duration of maintenance therapy with PARP inhibitors in patients with platinum sensitive recurrent ovarian cancer and long-term outcomes
Lucy Haggstrom, Yeh Chen Lee, Clare Scott, et al.
Lancet (London, England)
|
June 5, 2015
Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial
Michael Gnant, Georg Pfeiler, Peter C Dubsky, et al.
Page
of 24
Search research articles
Search
Showing results (201-210 of 237) with videos related to
Sort By:
Page
of 24
Genome Research
|
March 12, 2010
Age-dependent DNA methylation of genes that are suppressed in stem cells is a hallmark of cancer
Andrew E Teschendorff, Usha Menon, Aleksandra Gentry-Maharaj, et al.
Bulletin Du Cancer
|
March 26, 2023
Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria, Swiss AGO, BGOG, CEEGOG, GEICO, and SFOG regarding the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in epithelial ovarian cancer
Philipp Harter, Gerhard Bogner, Luis Chiva, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 1, 2021
Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer
Ignace Vergote, Isabelle Ray-Coquard, Daniel M Anderson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 9, 2016
Double-Blind, Placebo-Controlled, Randomized Phase III Trial Evaluating Pertuzumab Combined With Chemotherapy for Low Tumor Human Epidermal Growth Factor Receptor 3 mRNA-Expressing Platinum-Resistant Ovarian Cancer (PENELOPE)
Christian Kurzeder, Isabel Bover, Frederik Marmé, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 28, 2023
PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1/ENGOT-ov25 trial
Liselore Loverix, Ignace Vergote, Pieter Busschaert, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 12, 2024
Clinical evaluation of a low-coverage whole-genome test for detecting homologous recombination deficiency in ovarian cancer
Romain Boidot, Michael G B Blum, Marie-Pierre Wissler, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 4, 2016
ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer
Christian Marth, Ignace Vergote, Giovanni Scambia, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
June 13, 2015
European Network of Gynaecological Oncological Trial Groups' Requirements for Trials Between Academic Groups and Industry Partners--First Update 2015
Andreas du Bois, Alexander Reuss, Eric Pujade-Lauraine, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
October 22, 2024
How long is long enough? An international survey exploring practice variations on the recommended duration of maintenance therapy with PARP inhibitors in patients with platinum sensitive recurrent ovarian cancer and long-term outcomes
Lucy Haggstrom, Yeh Chen Lee, Clare Scott, et al.
Lancet (London, England)
|
June 5, 2015
Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial
Michael Gnant, Georg Pfeiler, Peter C Dubsky, et al.
Page
of 24